Table of Content

Introduction
Executive Summary
Glucagon-Like Peptide 1 Receptor Agonists: Overview
• Structure
• Mechanism of Action
Pipeline Therapeutics
• Comparative Analysis
Therapeutic Assessment
• Assessment by Product Type
• Assessment by Stage and Product Type
• Assessment by Route of Administration
• Assessment by Stage and Route of Administration
• Assessment by Molecule Type
• Assessment by Stage and Molecule Type
Glucagon-Like Peptide 1 Receptor Agonists – DelveInsight’s Analytical Perspective
In-depth Commercial Assessment
• Glucagon-Like Peptide 1 Receptor Agonists companies’ collaborations, Licensing, Acquisition -Deal Value Trends
Glucagon-Like Peptide 1 Receptor Agonists Collaboration Deals
• Company-Company Collaborations (Licensing / Partnering) Analysis
• Company-University Collaborations (Licensing / Partnering) Analysis
Late Stage Products (Phase III)
• Comparative Analysis
Tirzepatide: Eli Lilly and Company
• Product Description
• Research and Development
• Product Development Activities
Drug profiles in the detailed report?..
Mid Stage Products (Phase II)
• Comparative Analysis
IBI-362: Innovent Biologics
• Product Description
• Research and Development
• Product Development Activities
Drug profiles in the detailed report?..
Early Stage Products (Phase I)
• Comparative Analysis
Drug name: Company name
• Product Description
• Research and Development
• Product Development Activities
Drug profiles in the detailed report?..
Pre-clinical and Discovery Stage Products
• Comparative Analysis
Exenatide/insulin sublingual: Biolingus
• Product Description
• Research and Development
• Product Development Activities
Drug profiles in the detailed report?..
Inactive Products
• Comparative Analysis
Glucagon-Like Peptide 1 Receptor Agonists Key Companies
Glucagon-Like Peptide 1 Receptor Agonists Key Products
Glucagon-Like Peptide 1 Receptor Agonists- Unmet Needs
Glucagon-Like Peptide 1 Receptor Agonists- Market Drivers and Barriers
Glucagon-Like Peptide 1 Receptor Agonists- Future Perspectives and Conclusion
Glucagon-Like Peptide 1 Receptor Agonists Analyst Views
Glucagon-Like Peptide 1 Receptor Agonists Key Companies
Appendix



List of Figures


Figure 1 Total Products for Glucagon-Like Peptide 1 Receptor Agonists
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products


List of Tables


Table 1 Total Products for Glucagon-Like Peptide 1 Receptor Agonists
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products